College aantekeningen
Chapter 14: Closing remarks
Dit zijn mijn college aantekeningen van H14. Heel handig om zelf een samenvatting van te maken!
[Meer zien]Voorbeeld 1 van de 2 pagina's
Voorbeeld 1 van de 2 pagina's
In winkelwagen
Voorbeeld van de inhoud
Chapter 14: Closing remarksThe drug life cycle and the reward box
As we saw in the previous chapters, the developmental part of medicines should be shorter than the
part which comes afterwards. The return of investments (when the drug is on the market) should be
longer than the investment part in the ideal world. At some point in time, the patent will expire (after
20 years). There is a decline in income for the company, because now, there is a competition with
other companies and other (generic) compounds.
The reward box will increase the income of a
drug and they are trying to decrease the costs
of a new compound. In the innovation period,
the drug will cost money (financial loss), this is
the period of investments, the period of
extensive research and development. In the
monopoly period, the company has exclusive
rights to sell the drug (this is the patent period).
The length and the height of this period is
increasing. The length is determined by the
duration of the patent. You can try to
lengthened this to limit the duration of the
innovation period. The height is determined by the number of drugs you can sell and on the price you
can receive for your drug. The approval is determined by the policy makers, depending on the region
you are living in. The price is then determined locally. So, the profits are determined by the price
setting and this is determined by the policy makers. In the competitive period, there will be the loss
of exclusivity. There is a decline in income. In large extent, this has to do with the generics and the
biosimilars which are coming on the market. Here, we see the “normal” situation and how it is right
now. There are some levers for policy makers to alter the “box”: change something about the market
entry; the monopoly protection; the payer requirement; or the tax policy and incentives.
Measures affecting the reward box
The market entry levers include the changes in time and cost to obtain approval. In other words,
there are some ways to try to adjust the situation and try to optimize it. So, for example, try to have
an impact on the innovation period, think about:
Policies allowing earlier market access (exceptional circumstances)
o e.g. orphan diseases: So, if your drug is an orphan drug. It might be that your files are
quicker reviewed and it might be quicker approved! Thereby, you can shorten the
innovation period
o Conditional marketing approvals (CMA): These drugs got on the market, earlier than
in normal circumstances. They need very intense pharmacovigilance and a very
intense follow-up to still allow these medicines on the market
o Emergency use access (EUA)
Policies improving the efficiency of research and development (e.g. eCTA)
Expansion of approval (e.g. biosimilars)
Research grants
The master protocols: You can shorten the innovation period through looking at more
diseases at the same time with one drug; or to look at more different compounds in one
disease
How can we lengthen the monopoly protection period, what are the levers?
Policies on duration of market exclusivity
Pagina 1 van 2
Voordelen van het kopen van samenvattingen bij Stuvia op een rij:
√ Verzekerd van kwaliteit door reviews
Stuvia-klanten hebben meer dan 700.000 samenvattingen beoordeeld. Zo weet je zeker dat je de beste documenten koopt!
Snel en makkelijk kopen
Je betaalt supersnel en eenmalig met iDeal, Bancontact of creditcard voor de samenvatting. Zonder lidmaatschap.
Focus op de essentie
Samenvattingen worden geschreven voor en door anderen. Daarom zijn de samenvattingen altijd betrouwbaar en actueel. Zo kom je snel tot de kern!
Veelgestelde vragen
Wat krijg ik als ik dit document koop?
Je krijgt een PDF, die direct beschikbaar is na je aankoop. Het gekochte document is altijd, overal en oneindig toegankelijk via je profiel.
Tevredenheidsgarantie: hoe werkt dat?
Onze tevredenheidsgarantie zorgt ervoor dat je altijd een studiedocument vindt dat goed bij je past. Je vult een formulier in en onze klantenservice regelt de rest.
Van wie koop ik deze samenvatting?
Stuvia is een marktplaats, je koop dit document dus niet van ons, maar van verkoper lisaankersmit. Stuvia faciliteert de betaling aan de verkoper.
Zit ik meteen vast aan een abonnement?
Nee, je koopt alleen deze samenvatting voor €4,49. Je zit daarna nergens aan vast.
Is Stuvia te vertrouwen?
4,6 sterren op Google & Trustpilot (+1000 reviews)
Afgelopen 30 dagen zijn er 49497 samenvattingen verkocht
Opgericht in 2010, al 14 jaar dé plek om samenvattingen te kopen